CFO
MXCT icon

Callan Family Office’s MaxCyte MXCT Stock Holding History

Callan Family Office’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.4K Buy
112,989
+57,867
+105% +$54K ﹤0.01% 1099
2025
Q4 		$85.4K Buy
+55,122
New +$88K ﹤0.01% 1080

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Callan Family Office's MXCT Position: Q1 2026 in Review

Callan Family Office increased its MaxCyte (MXCT) stake by 105% in Q1 2026, buying an estimated $54K and bringing the position to 112,989 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

Callan Family Office first reported a position in MXCT in Q4 2025 and has held it in 2 quarters since. The position peaked at $85.4K in Q4 2025. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Callan Family Office held 112,989 shares of MaxCyte worth $79.4K as of Q1 2026.
  • Callan Family Office bought 57,867 MaxCyte shares in Q1 2026, an estimated $54K.
  • MaxCyte made up ﹤0.01% of Callan Family Office's portfolio in Q1 2026, its #1099 holding.
  • Callan Family Office first reported a position in MaxCyte in Q4 2025 and has held it in 2 quarters since.
  • Callan Family Office's MaxCyte position peaked at $85.4K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.